Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.

Jansman FG, Idzinga FS, Smit WM, de Graaf JC, Coenen JL, Sleijfer DT, Brouwers JR.

Clin Ther. 2005 Mar;27(3):327-35.

PMID:
15878386
2.

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

Aparicio T, Desramé J, Lecomte T, Mitry E, Belloc J, Etienney I, Montembault S, Vayre L, Locher C, Ezenfis J, Artru P, Mabro M, Dominguez S; AGEO.

Br J Cancer. 2003 Oct 20;89(8):1439-44.

3.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

4.

Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.

Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA.

Ann Oncol. 2002 Sep;13(9):1490-6.

PMID:
12196376
5.

Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.

Ulrich-Pur H, Kornek GV, Fiebiger W, Gedlicka C, Raderer M, Lenauer A, Depisch D, Lang F, Pidlich J, Scheithauer W.

Ann Oncol. 2001 Sep;12(9):1269-72.

PMID:
11697839
6.

Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.

Hoff PM, Saad ED, Pazdur R, Wolff R, Lassere Y, Bogaard KR, Abbruzzese JL.

Invest New Drugs. 2004 Aug;22(3):307-13.

PMID:
15122078
7.

Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.

Simpson D, Dunn C, Curran M, Goa KL.

Drugs. 2003;63(19):2127-56. Review.

PMID:
12962525
8.

Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.

Martinez J, Martin C, Chacon M, Korbenfeld E, Bella S, Senna S, Richardet E, Coppola F, Bas C, Hidalgo J, Escobar E, Reale M, Smilovich AM, Wasserman E.

Am J Clin Oncol. 2006 Feb;29(1):45-51.

PMID:
16462502
9.

Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.

Comella P, Massidda B, Palmeri S, Putzu C, De Rosa V, Izzo F, Fiore F, Casaretti R, Sandomenico C.

Anticancer Drugs. 2006 Sep;17(8):985-92.

PMID:
16940809
10.

Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.

Sheikh HY, Valle JW, Palmer K, Sjursen A, Craven O, Wilson G, Swindell R, Saunders MP.

Br J Cancer. 2007 Jan 15;96(1):38-43.

11.

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG.

J Clin Oncol. 2003 Jun 1;21(11):2059-69.

PMID:
12775730
12.

Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience.

Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J, Segura A, Gómez-Codina J.

Med Oncol. 2006;23(3):347-57.

PMID:
17018892
13.

Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.

Schüll B, Kornek GV, Schmid K, Raderer M, Ulrich-Pur H, Fiebiger W, Schneeweiss B, Lenauer A, Depisch D, Scheithauer W.

Onkologie. 2002 Aug;25(4):358-62.

PMID:
12232488
14.

Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.

Bajetta E, Beretta E, Di Bartolomeo M, Cortinovis D, Ferrario E, Dognini G, Toffolatti L, Buzzoni R.

Oncology. 2004;66(2):132-7.

PMID:
15138365
15.

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd.

J Clin Oncol. 2008 May 10;26(14):2311-9. doi: 10.1200/JCO.2007.13.1193. Epub 2008 Apr 7.

PMID:
18390971
16.

Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.

Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A.

Clin Colorectal Cancer. 2004 May;4(1):46-50.

PMID:
15207020
17.

Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.

Scheithauer W, Kornek GV, Schuell B, Ulrich-Pur H, Penz M, Raderer M, Lang F, Schneeweiss B, Lenauer A, Depisch D.

Ann Oncol. 2001 May;12(5):709-14.

PMID:
11432632
18.

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.

Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M, Bajetta R, Colombo A, Pusceddu S.

Ann Oncol. 2007 Nov;18(11):1810-6. Epub 2007 Sep 6.

PMID:
17823385
19.

The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.

Scartozzi M, Sobrero A, Gasparini G, Berardi R, Catalano V, Graziano F, Barni S, Zaniboni A, Beretta GD, Labianca R, Cascinu S; Italian Group for the Study of Digestive Tract Cancer.

Oncology. 2005;68(2-3):212-6. Epub 2005 Jul 7.

PMID:
16015036
20.

Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.

Scheithauer W, Kornek GV, Brugger S, Ullrich-Pur H, Valencak J, Raderer M, Fiebiger W, Kovats E, Lang F, Depisch D.

Cancer Invest. 2002;20(1):60-8.

PMID:
11853004

Supplemental Content

Support Center